- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Drug discovery
Recent successes don't change Lilly's outlook
February 9, 2011
J.K. WallEli Lilly and Co. can be credited with using acquisitions to unclog its product pipeline. It launched two drugs in the past
18 months, won market approval for a third and will likely get nods for two more drugs this year. Trouble is, they all have
paltry sales prospects.
MoreLilly collaboration with outside researchers yields first deal
February 8, 2011
Chris O'MalleyEli Lilly and Co.'s PD2 project attracted 30,000 compounds from researchers in 26 countries. And Lilly scientist Alan Palkowitz
said it's just the first of many such collaborations.
MoreEndocyte again changes terms of public offering
February 4, 2011
IBJ Staff and Bloomberg NewsThe West Lafayette-based biopharmaceutical company now is planning to offer at least 12.5 million shares, or 17 percent more
than previously announced, but at a lower price of $6 each.
MorePotential competitor to Lilly drug shows promise in study
February 2, 2011
IBJ Staff and Bloomberg NewsSanofi-Aventis's experimental diabetes drug lixisenatide, given to volunteer patients once a day, was at least as effective
as Eli Lilly and Co. and Amylin Pharmaceuticals Inc.'s twice-daily medicine Byetta, a study found.
MoreMarcadia may fetch up to $537 million in sale
February 2, 2011
J.K. WallThe December sale of Carmel-based Marcadia Biotech to Roche garnered at least $287 million—and as much as $537 million—for
the company’s owners and could lead the Marcadia management team to launch a firm using one of Marcadia’s experimental diabetes
medicines.
MoreLilly product gets boost; Wall Street yawns
January 26, 2011
J.K. WallEli Lilly and Co. probably will get approval for its newly acquired imaging agent used to diagnose Alzheimer’s disease,
but so far analysts are unimpressed.
MoreVanderbilt rejected by high court on Cialis patents
January 24, 2011
Bloomberg NewsSupreme Court justices on Monday left intact a ruling throwing out a lawsuit pressed by the Nashville, Tenn., university against
Eli Lilly's Icos subsidiary.
MoreDown on luck, Lilly finds comfort in pets
January 19, 2011
J.K. WallEli Lilly and Co. continues to misfire on getting new human medicines approved, but its animal health unit is on a roll.
MoreCarmel firm gets FDA approval for lice treatment
January 18, 2011
IBJ StaffParaPRO LLC's treatment, called Natroba, has a potential U.S. market of 6 million to 12 million infected children annually.
MoreLilly imaging drug isn't ready for approval, FDA says
January 18, 2011
Eli Lilly and Co.’s experimental drug to help identify plaque in the brain tied to Alzheimer's disease isn't ready for approval,
according to U.S. regulators.
MoreEndocyte prices IPO stock
January 14, 2011
J.K. WallThe West Lafayette-based drug development firm intends to sell 6.15 million shares for $13 to $15 apiece. That would fetch
$80 million to $92 million.
MorePanel says Lilly’s Solpura isn’t ready for approval
January 12, 2011
Bloomberg NewsEli Lilly and Co. failed to win an FDA advisory panel’s recommendation to introduce the first pancreatic enzyme that
isn’t derived from pig parts.
MoreLilly partner moves up timetable for diabetes drug
January 11, 2011
Bloomberg NewsAmylin Pharmaceuticals Inc., rebuffed twice in its bid for U.S. approval of a weekly diabetes drug, will meet its timetable
and submit a heart-safety study to regulators by the end of 2011, its CEO said.
MoreLilly's Solpura may lack data to prove effectiveness
January 10, 2011
Bloomberg NewsOutside advisers to the FDA will meet Jan. 12 to review whether the drug should be approved for people with pancreas insufficiency
caused by cystic fibrosis, chronic pancreatitis or other conditions.
MoreLilly, other big drugmakers shut out by FDA in 2010
January 3, 2011
IBJ Staff and Bloomberg NewsRegulators cleared 21 medicines, the fewest since 2007, for sale last year. It was the first time in a decade that Pfizer
Inc., the world's largest drugmaker, as well as Lilly, Merck & Co. and Bristol-Myers Squibb Co. were shut out at the same
time, according to agency records.
MoreRoche acquires Marcadia Biotech
December 30, 2010
Chris O'MalleyMarcadia Biotech Inc., a Carmel-based biopharmaceutical company founded by prominent scientists from Eli Lilly and Co. in
2006, has been acquired by Swiss life sciences giant Roche.
MoreContrarians think it's new day for Lilly
December 1, 2010
J.K. WallThe trouble-free market approval obtained by Eli Lilly and Co. for a new underarm testosterone treatment brightened the company’s
outlook—at least for one of the few optimistic analysts covering the company.
MoreLilly, Acrux receive FDA approval for Axiron
November 24, 2010
IBJ Staff and Bloomberg NewsThe companies believe the underarm testosterone solution has the potential to realize sales of more than $1 billion a year
in the United States.
MoreLilly scores series of small victories
November 17, 2010
J.K. WallThe Indianapolis-based drugmaker finally won FDA approval for its antidepressant Cymbalta to treat chronic pain and fended
off a patent challenge to rising-star cancer drug Alimta, but got a ratings downgrade on its debt.
MoreStudy: Arthritis drug co-developed by Lilly shows promise
November 12, 2010
IBJ Staff and Bloomberg NewsLilly paid $90 million in 2009 to acquire the global rights to the treatment in a bid to beef up its pipeline of medications
for autoimmune diseases.
MoreMoody's downgrades long-term ratings for Eli Lilly
November 9, 2010
Associated PressMoody's Investors Service on Monday lowered the long-term ratings of Lilly one notch, to A2 from A1, citing a wave of patent
expirations the drugmaker faces in coming years.
MoreLilly makes $300M deal for Philadelphia drug company
November 8, 2010
J.K. WallEli Lilly said it will acquire Avid Radiopharmaceuticals, maker of an experimental agent that could help identify patients
with Alzheimer's disease. The price could climb to $800 million if the agent is commercially successful.
MoreSeeking growth, Lilly dumps Singapore for China
November 3, 2010
J.K. WallAfter recently deciding to close a research center in Singapore, Indianapolis-based Eli Lilly and Co. has decided to open
a diabetes research center in China in the second half of 2011, further ramping up the drugmaker's presence in the world's
fastest-growing pharmaceutical market.
MoreLilly to open diabetes research center in China
November 2, 2010
IBJ StaffIndianapolis-based Eli Lilly and Co. plans to open a diabetes research center in China, the drugmaker said Tuesday, citing
the high incidence of the disease there.
MoreEli Lilly will have to beat odds to meet drug-rollout goals
October 30, 2010
J.K. WallEli Lilly and Co. executives have said repeatedly that the company’s bulging pipeline will produce two new drugs per
year, beginning in 2013. But only three times in the past six decades has Lilly been able to launch two or more new drugs
in back-to-back years.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
Good ole' Obamacare. Thanks liberals and those who didn't bother to vote.
Yes. Blame those who were too lazy to go vote Obama out and those who voted him in again. That's my take on it. I know folks won't get it on the left. OK. Start berating me now!
Serioulsy, people are AGINST this project? Most communities would be salivating over a project like this. You'd rather have an empty eye-sore gas station and shacks posing as apartments? This project is exactly what BR needs. BUILD IT MR MAYOR. And yes, I am a BR resident, and have been for 20 years.
As a St. Vincent employee of over 20 years, I am saddened and disheartened by this announcement. Unfortunately, as the healthcare "industry" continues on this political and corporate path, all that St. Vincent Hospital has stood for spiritually for its employees and this community is being sucked dry. I know it truly has no choice. It is not just Obamacare or just competition or just any single thing. This trend started long before I was even born when the government became involved in healthcare and it became an "industry." I grieve for those who will lose their jobs, one of whom may be me, but I also grieve for this hospital which I have served for over 20 years. May God give us and it the grace to withstand the future of healthcare.
Why do people constantly harp on this issue and act ignorant about what a city population measures? A city's population is the city's population. There is no argument or debate about it. If you want to measure the density of a city--measure it. If you want to measure the size of a metropolitan area, then measure the metropolitan population. City boundaries cover different sized areas--and they always have (though the disparity has probably increased since about 1900 or so when more cities began annexing their surrounding communities). For example, San Francisco only covers 49 square miles while Houston cover nearly 600 square miles. No one argues about the population rankings of either city even though they clearly cover extremely different sized areas. Indianapolis is the 13 largest city by population in the U.S. That is a fact. While the population of a metropolitan area may give you a better sense of how large a community is, as noted, even metro areas can vary widely in the size of geographic area they cover--so that is not a perfect comparison either.